In the last trading session, 1.57 million shares of the Immunome Inc (NASDAQ:IMNM) were traded, and its beta was 2.00. Most recently the company’s share price was $7.40, and it changed around $0.05 or 0.68% from the last close, which brings the market valuation of the company to $643.44M. IMNM currently trades at a discount to its 52-week high of $21.72, offering almost -193.51% off that amount. The share price’s 52-week low was $5.15, which indicates that the current value has risen by an impressive 30.41% since then. We note from Immunome Inc’s average daily trading volume that its 10-day average is 1.27 million shares, with the 3-month average coming to 1.15 million.
Immunome Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended IMNM as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight.
Immunome Inc (NASDAQ:IMNM) trade information
Instantly IMNM has showed a green trend with a performance of 0.68% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 7.56 on recent trading dayincreased the stock’s daily price by 2.12%. The company’s shares are currently down -30.32% year-to-date, but still up 33.09% over the last five days. On the other hand, Immunome Inc (NASDAQ:IMNM) is -18.14% down in the 30-day period. We can see from the shorts that 11.13 million shares have been sold at a short interest cover period of 8.82 day(s).
The consensus price target as assigned by Wall Street analysts is $33, which translates to bulls needing to increase their stock price by 77.58% from its current value. Analyst projections state that IMNM is forecast to be at a low of $23 and a high of $35.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -38.15%. Immunome Inc earnings are expected to increase by 48.00% in 2025, but the outlook is positive 21.19% per year for the next five years.
IMNM Dividends
Immunome Inc’s next quarterly earnings report is expected to be released on 2025-Mar-18.
Immunome Inc (NASDAQ:IMNM)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 16.23% of Immunome Inc shares, and 58.02% of them are in the hands of institutional investors. The stock currently has a share float of 69.26%. Immunome Inc stock is held by 172.0 institutions, with REDMILE GROUP, LLC being the largest institutional investor. By 2024-06-30, it held 8.1579% of the shares, which is about 4.89 million shares worth $59.16 million.
FMR LLC, with 7.0257% or 4.21 million shares worth $50.95 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund and T. Rowe Price Small-Cap Stock Fund, Inc. were the top two Mutual Funds as of Jan 31, 2025 . The former held 3.07 shares worth $22.73 million, making up 3.53% of all outstanding shares. On the other hand, T. Rowe Price Small-Cap Stock Fund, Inc. held roughly 1.96 shares worth around $14.48 million, which represents about 2.25% of the total shares outstanding.
